Nasal administration
First Claim
1. A method of treating migraine in a human subject by delivering a powdered substance comprising sumatriptan to the posterior region of a nasal cavity of the human subject, the method comprising:
- inserting a nosepiece into the nasal cavity of the human subject;
inserting a mouthpiece into the mouth of the human subject;
the subject exhaling through the mouthpiece to cause closure of the oropharyngeal velum of the subject, wherein the mouthpiece is fluidly connected to the nosepiece, whereby exhaled air from an exhalation breath is delivered through the nosepiece; and
delivering the powdered substance through the nosepiece to the posterior region of the nasal cavity of the subject via a bi-directional flow through the nasal cavity, wherein the powdered substance is delivered from a container chamber which houses a container which contains the powdered substance, and the container chamber includes an inlet which is fluidly connected to the mouthpiece and an outlet which is fluidly connected to the nosepiece, whereby exhaled air from the exhalation breath acts to entrain the powdered substance and deliver the powdered substance through the nosepiece;
wherein the powdered substance consists essentially of sumatriptan succinate without introduced excipients or adjuvants and;
wherein the powdered substance has an untapped bulk density of between about 0.3 g/ml and about 0.5 g/ml;
wherein the powdered substance comprises a particle size distribution of 10% less than about 20 μ
m, 50% less than about 50 μ
m, and 90% less than about 150 μ
m.
6 Assignments
0 Petitions
Accused Products
Abstract
A delivery device for and method of delivering a powdered substance, in particular a triptan, such as sumatriptan, to the posterior region of a nasal cavity of a subject, in particular for the treatment of headaches, for example, cluster headaches and migraine, and neuropathic pain, the delivery device comprising: a nosepiece (47) for insertion into a nasal cavity of a subject through which the powdered substance is delivered to the posterior region of the nasal cavity of the subject, in particular the upper posterior two thirds of the nasal cavity; and a substance supply unit (16) which is operable to deliver the powdered substance through the nosepiece (47).
-
Citations
46 Claims
-
1. A method of treating migraine in a human subject by delivering a powdered substance comprising sumatriptan to the posterior region of a nasal cavity of the human subject, the method comprising:
-
inserting a nosepiece into the nasal cavity of the human subject; inserting a mouthpiece into the mouth of the human subject; the subject exhaling through the mouthpiece to cause closure of the oropharyngeal velum of the subject, wherein the mouthpiece is fluidly connected to the nosepiece, whereby exhaled air from an exhalation breath is delivered through the nosepiece; and delivering the powdered substance through the nosepiece to the posterior region of the nasal cavity of the subject via a bi-directional flow through the nasal cavity, wherein the powdered substance is delivered from a container chamber which houses a container which contains the powdered substance, and the container chamber includes an inlet which is fluidly connected to the mouthpiece and an outlet which is fluidly connected to the nosepiece, whereby exhaled air from the exhalation breath acts to entrain the powdered substance and deliver the powdered substance through the nosepiece; wherein the powdered substance consists essentially of sumatriptan succinate without introduced excipients or adjuvants and; wherein the powdered substance has an untapped bulk density of between about 0.3 g/ml and about 0.5 g/ml; wherein the powdered substance comprises a particle size distribution of 10% less than about 20 μ
m, 50% less than about 50 μ
m, and 90% less than about 150 μ
m. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)
-
-
15. A method of treating migraine in a human subject by delivering a powdered sumatriptan substance to a posterior region of a nasal cavity of the subject, comprising:
-
inserting a nosepiece into a nostril of the subject; closing the oropharyngeal velum of the subject; and delivering the powdered sumatriptan substance through the nosepiece to the posterior region of the nasal cavity of the subject via a bi-directional air flow through the nasal cavity of the subject, wherein the powdered sumatriptan substance is delivered from a substance containing unit which contains the powdered sumatriptan substance, and the substance containing unit includes an inlet and an outlet which is fluidly connected to the nosepiece, whereby the bi-directional air flow is delivered through the inlet of the substance containing unit and acts to entrain the powdered sumatriptan substance and deliver the powdered sumatriptan substance from the outlet and through the nosepiece; wherein the powdered sumatriptan substance has an untapped bulk density of between about 0.3 g/ml and about 0.5 g/ml; and wherein the powdered sumatriptan substance has a particle size distribution of 50% greater than about 30 μ
m. - View Dependent Claims (16, 17, 18, 19, 20, 21, 22)
-
-
23. A method of treating migraine in a human subject by delivering a powdered sumatriptan substance to a posterior region of a nasal cavity of the subject, comprising:
-
inserting a nosepiece into a nostril of the subject; inserting a mouthpiece into a mouth of the subject; the subject exhaling through the mouthpiece to cause closure of the oropharyngeal velum of the subject, wherein the mouthpiece is fluidly connected to the nosepiece, whereby exhaled air from an exhalation breath is delivered through the nosepiece; and delivering the powdered sumatriptan substance through the nosepiece to the posterior region of the nasal cavity of the subject via a bi-directional air flow through the nasal cavity of the subject, wherein the powdered sumatriptan substance is delivered from a substance containing unit which contains the powdered sumatriptan substance, and the substance containing unit includes an inlet which is fluidly connected to the mouthpiece and an outlet which is fluidly connected to the nosepiece, whereby exhaled air from the exhalation breath is delivered through the inlet of the substance containing unit and acts to entrain the powdered sumatriptan substance and deliver the powdered sumatriptan substance from the outlet and through the nosepiece; wherein the powdered sumatriptan substance has an untapped bulk density of between about 0.3 g/ml and about 0.5 g/ml; and wherein the powdered sumatriptan substance has a particle size distribution of 50% greater than about 30 μ
m. - View Dependent Claims (24, 25, 26, 27, 28, 29, 30)
-
-
31. A device for delivering a powdered sumatriptan substance to a posterior region of a nasal cavity of a subject, comprising:
-
a nosepiece configured for fitting to a nostril of the subject; and a substance containing unit connected to the nosepiece, the substance containing unit comprising the powdered sumatriptan substance to be delivered to the nasal cavity of the subject, wherein the powdered sumatriptan substance has an untapped bulk density of between about 0.3 g/ml and about 0.5 g/ml, and wherein the powdered sumatriptan substance has a particle size distribution of 50% greater than about 30 μ
m;wherein the device is configured such that, when the nosepiece is fitted to the nostril of the subject, oral exhalation by the subject through the substance containing unit and the nosepiece acts to close the oropharyngeal velum of the subject and produce an exhalation flow passing into one nasal passage of the subject and out of the other nasal passage of the subject, thereby achieving a bi-directional exhalation flow for delivering the powdered sumatriptan substance to the posterior region of the nasal cavity of the subject. - View Dependent Claims (32, 33, 34, 35, 36, 37, 38)
-
-
39. A device for delivering a powdered sumatriptan substance to a posterior region of a nasal cavity of a subject, comprising:
-
a mouthpiece configured for fitting to an oral cavity of the subject; a nosepiece configured for fitting to a nostril of the subject; and a substance containing unit connected to the nosepiece, the substance containing unit comprising the powdered sumatriptan substance to be delivered to the nasal cavity of the subject, wherein the powdered sumatriptan substance has an untapped bulk density of between about 0.3 g/ml and about 0.5 g/ml, and wherein the powdered sumatriptan substance has a particle size distribution of 50% greater than about 30 μ
m;wherein the device is configured such that, when the nosepiece is fitted to the nostril of the subject and the mouthpiece is fitted to the oral cavity of the subject, oral exhalation by the subject through the mouthpiece acts to close the oropharyngeal velum of the subject and produce an exhalation air flow which entrains the powdered sumatriptan substance, passes into one nasal passage of the subject and out of the other nasal passage of the subject, thereby achieving a bi-directional exhalation flow for delivering the powdered sumatriptan substance to the posterior region of the nasal cavity of the subject. - View Dependent Claims (40, 41, 42, 43, 44, 45, 46)
-
Specification